An Observational Study Validating a Score That Quantifies the Therapeutic Response to Treatment With Norditropin®

Novo Nordisk A/S121 enrolled

Overview

This observational study is conducted in Europe. The aim of this observational study is to investigate the changes in a score (GET-score) which includes quality of life, body composition and cholesterol metabolism in patients on growth hormone treatment. The GET score stands for: Growth hormone deficiency and Efficacy of Treatment, and is a quantitative measurement of the efficacy of the treatment with growth hormone in adults.

Study Type

OBSERVATIONAL

Enrollment

121

Conditions

Growth Hormone Disorder Adult Growth Hormone Deficiency

Interventions

somatropinDRUG

For s.c. (under the skin) injection. Start dose and frequency to be prescribed by the physician as a result of the normal clinical evaluation

No treatment givenOTHER

Control group not receiving treatment

Eligibility

Sex: ALLMin age: 18 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Severe acquired growth hormone deficiency * No treatment with somatropin in the last 24 months before study participation * Written informed consent Exclusion Criteria: * Contraindications for the treatment with somatropin

Locations (1)

Unnamed facility

Mainz, Germany

Outcomes

Primary Outcomes

Improvement of an integrated score which consists of Quality of Life (QoL), body composition, lipid metabolism, bone mineral density